New In Vitro Study Presented at the American College of Cardiology Meeting Suggests Omega-3 Fatty Acid EPA Pre-Treatment Reduces Oxidative Damage and May Provide Atheroprotective Benefit Versus Other Triglyceride Lowering Agents